This publication is a product of the HEALing Communities Study (HCS) and informed by the Communities That HEAL (CTH) Intervention Manual as well as integral contributions from research and community partners across four research sites. This guide was developed in recognition of the need to center community engagement throughout the efforts to address the opioid overdose crisis.
This guide exists to help communities decrease opioid overdose deaths; it includes tools and real-world examples that can be used to build and strengthen community coalitions that work to reduce opioid overdose deaths.

The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.

This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.

The second supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and professionals who provide services for them.

The third supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. A compendium of resources for professionals who work with parents involved with child welfare.

An analysis of the 2022 DAWN data presents: (1) nationally representative weighted estimates of all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; (3) nationally representative weighted estimates of opioid- related ED visits by type of opioid, (4) drugs involved in polysubstance ED visits, and (5) the identification of newly mentioned drugs in 2022.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.